4.95
-0.87(-14.95%)
Currency In USD
| Previous Close | 5.82 |
| Open | 5.07 |
| Day High | 5.48 |
| Day Low | 4.95 |
| 52-Week High | 31.7 |
| 52-Week Low | 2.01 |
| Volume | 22,616 |
| Average Volume | 2.48M |
| Market Cap | 6.56M |
| PE | -0.38 |
| EPS | -13.07 |
| Moving Average 50 Days | 6.14 |
| Moving Average 200 Days | 4.22 |
| Change | -0.87 |
If you invested $1000 in Galecto, Inc. (GLTO) since IPO date, it would be worth $13.2 as of November 10, 2025 at a share price of $4.95. Whereas If you bought $1000 worth of Galecto, Inc. (GLTO) shares 3 years ago, it would be worth $114.77 as of November 10, 2025 at a share price of $4.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Galecto Announces Acquisition of Damora Therapeutics
GlobeNewswire Inc.
29 minutes ago
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms Damora Therapeutics, the sixth
Galecto Reports Third Quarter 2025 Operating and Financial Results
GlobeNewswire Inc.
Nov 06, 2025 9:30 PM GMT
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for t
Galecto to Highlight GB3226 Program at ASH 2025
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acute myeloid leukemia (AML) BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Galecto, In